SCHEMBL4769045

SCHEMBL4769045

c1ccc(-c2nc(NCCN3CCCC3)cc(-c3cccnc3)n2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 7/20 0.48
HDAC6 Q9UBN7 5/20 0.46
HIF1A Q16665 1/20 0.46
CYP2A6 P11509 1/20 0.45
ACHE P22303 1/20 0.45
CYP3A4 P08684 2/20 0.44
CFTR P13569 1/20 0.44
CYP2C9 P11712 1/20 0.44
ACP1 P24666 1/20 0.44
SMARCA2 P51531 1/20 0.44
KDM4E B2RXH2 1/20 0.44
KDM6B O15054 1/20 0.44
KDM6A O15550 1/20 0.44
KDM4A O75164 1/20 0.44
KDM4B O94953 1/20 0.44
CHRNA1 P02708 1/20 0.44
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
KDM5A P29375 1/20 0.44
OPRM1 P35372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774987 0.92 ADORA2A (0.46) HDAC1HIF1ACYP2A6CYP3A4CFTR
SCHEMBL2238217 0.86 HDAC1 (0.42) HDAC1HDAC6HIF1ACYP2A6CYP3A4
SCHEMBL2238203 0.86 HDAC1 (0.42) HDAC1HDAC6HIF1ACYP2A6CYP3A4
SCHEMBL4774925 0.86 HDAC1 (0.40) HDAC1HDAC6HIF1ACYP2A6CYP3A4
SCHEMBL2240387 0.86 HDAC1 (0.42) HDAC1HDAC6HIF1ACYP2A6CYP3A4
SCHEMBL4777383 0.84 METAP1 (0.47) HDAC1HDAC6HIF1ACYP3A4CYP2C9
SCHEMBL28894858 0.81 HDAC1 (0.48) HDAC1HDAC6ACHECYP3A4CYP2C9
SCHEMBL30085849 0.81 HDAC1 (0.48) HDAC1HDAC6ACHECYP3A4CYP2C9
SCHEMBL2240174 0.81 CYP3A4 (0.42) HDAC1HIF1ACYP2A6CYP3A4CYP2C9
SCHEMBL11968349 0.81 CYP3A4 (0.47) HDAC1HIF1ACYP2A6CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed